<DOC>
	<DOCNO>NCT00465751</DOCNO>
	<brief_summary>The purpose study determine whether chenodeoxycholic acid decrease de novo hepatic lipogenesis , hepatic fat content , hepatic triglyceride production plasma triglyceride concentration improves hepatic glucose metabolism patient metabolic syndrome , Familial Hypertriglyceridemia Familial Combined Hyperlipidemia .</brief_summary>
	<brief_title>Effects FXR Activation Hepatic Lipid Glucose Metabolism</brief_title>
	<detailed_description>Insulin resistance find key pathophysiological factor metabolic syndrome may precede onset impaired glucose tolerance , diabetes dyslipidemia . Recently , nonalcoholic fatty liver disease ( NAFLD ) , identify another feature syndrome . Importantly , close relation liver fat content hepatic insulin sensitivity describe . We hypothesize activation FXR chenodeoxycholic acid decrease hepatic de novo lipogenesis subsequently hepatic fat content triglyceride production . The decrease liver fat content associate improved hepatic insulin sensitivity decrease hepatic glucose production . Patients diagnose metabolic syndrome , familial hypertriglyceridemia familial combine hyperlipidemia recruit outpatient department Division Endocrinology , Diabetology Clinical Nutrition , University Hospital Basel . Eligible patient admit CRC metabolic study , include baseline blood sample measurement hormone , cytokine adipokines , euglycemic-hyperinsulinemic clamp study assessment glucose turnover insulin sensitivity vivo NMR study determine intrahepatic intramyocellular lipid content . Patients alternatively receive chenodeoxycholic acid placebo . The study population compare group age , gender weight match normolipidemic control .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<mesh_term>Hyperlipidemia , Familial Combined</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type IV</mesh_term>
	<mesh_term>Chenodeoxycholic Acid</mesh_term>
	<criteria>1 . Age 18 65 year . 2 . Patients metabolic syndrome define presence &gt; = 3 follow criterion : Abdominal obesity ( waist circumference &gt; 102 cm men , &gt; 88 cm woman ) Fasting plasma triglyceride &gt; 1.7 mmol/l HDL cholesterol &lt; 1.0 mmol/l men &lt; 1.3 mmol/l woman Blood pressure &gt; 130/85 mmHg antihypertensive medication Fasting plasma glucose &gt; 6.1 mmol/l 3 . Patients Familial Combined Hyperlipidemia characterize follow criterion : Fasting plasma triglyceride &gt; 1.7 mmol/l Fasting plasma apolipoprotein B concentration &gt; 1.2 g/l Family history hypertriglyceridemia and/or hypercholesterolemia present least 1 additional first degree family member 4 . Patients Familial Hypertriglyceridemia characterize follow criterion : Fasting plasma triglyceride &gt; 2.3 mmol/l Family history hypertriglyceridemia least 1 additional first degree family member Absence metabolic syndrome define 5 . Controls fulfil follow criterion : Non smoking . No current previous organ systemic disease ( include diabetes lipid disorder ) . Plasma triglycerides cholesterol within normal range ( see exclusion criterion ) . Plasma glucose concentration &lt; 6.1 mmol/l Subjects meet criterium 1 criterion 2 . 5. eligible study . 1 . Any significant hepatic , cardiac , pulmonary , renal , neurological , musculoskeletal , hematological endocrine disease . 2 . Any form primary secondary hyperlipidemia metabolic syndrome , FHTG FCHL . [ These may include : Familial hypercholesterolemia Familial defective apolipoprotein B ( assess family history lipid profile ) , Familial Dysbetalipoproteinemia ( assess apo E genotyping ) , hypothyroidism , nephrotic syndrome , diabetes mellitus , cholestatic liver disease , drug induce hyperlipidemia ( thiazide &gt; 25 mg/d , non cardioselective betablockers , isotretinoin , systemic glucocorticoid , cyclosporin A , tacrolimus , non nucleoside HIV protease inhibitor ) ] . 3 . Plasma TG level &gt; 12 mmol/l past time point study . 4 . History acute pancreatitis 5 . History cardiovascular disease , i.e . coronary artery disease , cerebrovascular disease , peripheral vascular disease , assess medical history , physical exam . Additionally , stress test perform subject MS FCHL risk CHD ( see ) . 6 . Pregnant Breast Feeding woman 7 . Woman childbearing potential use reliable method birth control oral contraceptive IUD . 8 . Alcohol intake great 1 drink daily . 9 . Cigarette smokers 10 . History claustrophobia 11 . Ferromagnetic implant include pacemaker . 12 . Subjects refuse unable give write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>